{'fraction_non_alphanumeric': 0.03414634146341464, 'fraction_numerical': 0.016260162601626018, 'mean_word_length': 5.222222222222222, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Denosumab--a new efficient osteoporosis therapy].

Denosumab is a new biological (monoclonal antibody) antiresorptive treatment of osteoporosis which is administrated as a subcutaneous 60 mg injection twice a year. Compared with placebo, three years of treatment increases bone mineral density by 6-9% and decreases the risk of vertebral and hip fractures by 68% and 40%, respectively, in postmenopausal women with osteoporosis. In men with iatrogenic hypogonadism due to prostate cancer, the risk of vertebral fractures is decreased by 62%. Side effects are few, but the treatment may increase risk of infections.